| Objective: To determine the clinical efficacy and safety of "Fuzi Wenshen Decoction" by observing various indicators.The clinical characteristics of Professor Huang Guihua in treating irritable bowel syndrome were explored based on the composition characteristics of "Fuzi Wenshen Decoction",providing new perspectives and thoughts for the treatment of this disease,hoping to provide well-being to patients suffering from this disease.Methods: Sixty patients who met the inclusion criteria were randomly divided into an experimental group and a control group,with 30 patients in each group.The experimental group was given "Fuzi Wenshen Recipe" with oral addition and subtraction,1 dose per day,divided into warm clothes in the morning and evening;the control group was given trimebutine maleate for oral administration.Patients in the two groups were treated continuously for 1 month.Detailed data were collected before and after treatment on TCM symptom scores,IBS symptom severity scores,IBS quality of life scores,and adverse reactions,and 2 weeks and 1 month after the end of treatment.Patients who were effective in treatment were followed up to record their recurrence.Collect relevant data,and use SPSS21.0 for statistical analysis of all data.Results:1.Comparison of overall efficacy: Among the 30 patients in the control group,the number of cured,markedly effective and effective cases were 1,2,and 13 respectively,with a total effective rate of 53.3%.Among the 30 patients in the experimental group,the cured,markedly effective and effective The number of cases was 3,6 and 15 respectively,and the total effective rate was 80%.The overall effect of the experimental group was better than that of the control group,with statistical differences(P <0.05).2.Comparison of the total scores of TCM symptoms: There was no significant difference in the total scores of TCM symptoms between the two groups of patients before treatment(P> 0.05),which was comparable.After treatment,the symptoms of TCM in all patients were improved compared with those before treatment(P <0.05),and the treatment effect of the patients in the experimental group was significantly better than that in the control group(P <0.05).3.Comparison of single symptom scores: There was no significant difference in the individual symptom scores between the two groups of patients before treatment(P> 0.05),and they were comparable.After treatment,the symptoms of the two groups of patients were improved compared with the previous one(P <0.05).In terms of comparison between the two groups,when treating the five symptoms of changing stool characteristics,abnormal stool frequency,diarrhea,decreased appetite,and fatigue The curative effect was equivalent(P> 0.05);but the experimental group was better than the control group in treating the three symptoms of abdominal cold pain,chills,cold limbs,and waist and knee weakness(P <0.05).4.Comparison of IBS-SSS symptom severity score: There was no significant difference in disease severity between the two groups of patients before treatment(P> 0.05),and they were comparable.After treatment,the disease severity of both groups of patients was improved compared with that before treatment(P <0.05),and the degree of improvement in the experimental group was significantly better than that in the control group(P <0.05).5.Comparison of IBS-QOL quality of life scores: There was no significant difference in the quality of life between the two groups of patients before treatment(P> 0.05),which was comparable.After treatment,the quality of life of the two groups of patients was improved compared with that before treatment(P<0.05),and the improvement effect of the experimental group was significantly better than the control group(P <0.05).6.Comparison of recurrence rates: Two weeks and one month after the end of the course of treatment,patients who had been treated effectively were followed up after treatment.A total of 16 patients were followed up in the control group,3 of whom relapsed after 2 weeks,with a recurrence rate of 18.7%,and 7 patients relapsed after 1 month,with a recurrence rate of 43.8%.A total of 24 patients were followed up in the experimental group,and 1 relapsed after 2 weeks.It was 4.2%,and 3 patients relapsed after 1 month.The recurrence rate was 12.5%.Compared with the two groups,there was no significant difference in the recurrence rate between the experimental group and the control group after 2 weeks(P> 0.05),but the recurrence rate of the experimental group was lower than that of the control group after one month(P <0.05).7.Safety comparison: During treatment and follow-up,the vital signs,physical examination and related auxiliary examinations of the two groups of patients were not significantly abnormal,and no adverse reactions occurred.Conclusions: The overall effect of Fuzi Wenshen Recipe in treating irritable bowel syndrome of spleen and kidney yang deficiency type(diarrhea type)is better than that of the control group using only trimebutine maleate capsules.Both the experimental group and the control group can make patients' The clinical symptoms improved,and the two groups had similar treatment effects on changes in stool characteristics,abnormal stool frequency,diarrhea,decreased appetite,and fatigue.However,the experimental group treated three symptoms of abdominal cold pain,chills,cold limbs,and waist and knee weakness.The curative effect was better than that of the control group.In addition to improving the clinical symptoms of patients,Fuzi Wenshen Recipe can also reduce the severity of the patient's condition and improve the quality of life of the patient.Moreover,the treatment effect is longer than that of western medicine,and the recurrence rate is low.It is safe throughout the treatment process. |
PDF Full Text Request